Berberine ameliorates intestinal mucosal barrier dysfunction in nonalcoholic fatty liver disease (NAFLD) rats

被引:10
|
作者
Wang, Yuzhen [1 ]
Cui, Suxian [2 ]
Zheng, Jimin [1 ]
Li, Yueqin [1 ]
Li, Pingping [1 ]
Hou, Hongtao [1 ]
机构
[1] Hebei Gen Hosp, Dept Gastroenterol, Shijiazhuang 050051, Hebei, Peoples R China
[2] Hebei Med Univ, Dept Gastroenterol, Shijiazhuang 050017, Hebei, Peoples R China
关键词
Nonalcoholic fatty liver disease; Berberine; Intestinal mucosal barrier; ENDOTOXEMIA; DIET; NOD1;
D O I
10.1016/j.jksus.2020.03.019
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: To study the protective role of berberine (BBR) against nonalcoholic fatty liver disease (NAFLD) on intestinal barrier via investigating its effect on intestinal permeability and intestinal innate immune system in a rat model. Method: Sprague-Dawley rats were randomly divided into three groups: control rats (group N), high-fat diet (HFD) model rats (group M) and BBR-treated rats (group B). Rats in group M and group B were fed with HFD for 12 weeks to induce NAFLD. Rats in group B were then received 4 weeks of BBR administration with continuous HFD feeding. Samples were collected at 16th week. Results: HFD feeding increased the body weight of rats and caused liver steatosis as indicated by hematoxylin & eosin (H&E) staining. Analysis of serum parameters showed that alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), endotoxin, interleukin-1 beta (IL-1 beta), interleukin-18 (IL-18), and tumor necrosis factor-alpha (TNF-alpha) were significantly higher in group M as compared group N. These results confirmed the successful establishment of NAFLD in rats. With 4 weeks of BBR administration, body weight of group B decreased significantly as compared with group M. Serum levels of ALT, AST, TC, TG, endotoxin, IL-1 beta, IL-18 and TNF-alpha reduced significantly and hepatocyte steatosis ameliorated. RT-PCR and Western blot analysis showed that BBR reduced the elevated mRNA and protein expressions of innate immune response elements NOD1, NOD2 and NLRP3 that were caused by HFD. BBR also antagonized the effect of NAFLD on Caspase-1 and Claudin-4 protein expressions. Conclusions: BBR alleviates endotoxemia, reduces serum lipids, increases liver function, reduces systemic inflammation and diminishes liver inflammation and steatosis in NAFLD rats. The protective effect of BBR against NALFD is achieved through ameliorating intestinal mucosal barrier dysfunction partly by improving permeability of intestinal mucosa and modulating intestinal innate immune components. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:2534 / 2539
页数:6
相关论文
共 50 条
  • [41] Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH)
    Ota, Tsuguhito
    CAROTENOIDS: BIOSYNTHETIC AND BIOFUNCTIONAL APPROACHES, 2021, 1261 : 223 - 229
  • [42] The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease
    Puri, Puneet
    Sanyal, Arun J.
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 121 - +
  • [43] A Lipidomic Readout of Disease Progression in Nonalcoholic Fatty Liver Disease (NAFLD)
    Pacana, Tommy
    Min, Hae K.
    Patel, Vaishali
    Katainen, Riikka
    Vihervaara, Terhi
    Mirshahi, Faridoddin
    Puri, Puneet
    Sanyal, Arun J.
    HEPATOLOGY, 2013, 58 : 531A - 531A
  • [44] Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
    Kaswala, Dharmesh H.
    Lai, Michelle
    Afdhal, Nezam H.
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) : 1356 - 1364
  • [45] Berberine Prevents High Fat Died-Induced Nonalcoholic Fatty Liver Disease in Rats
    Zhou, Xiqiao
    Wang, Ying
    Chen, Xuan
    Qin, Kang
    Gao, Shujuan
    Cao, Risheng
    Zhou, Huiping
    Shi, Ruihua
    GASTROENTEROLOGY, 2013, 144 (05) : S1020 - S1020
  • [46] Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD)
    Xin, Xin
    Chen, Cheng
    Hu, Yi-Yang
    Feng, Qin
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 117
  • [47] Nonalcoholic fatty liver disease (NAFLD): Approach in the adolescent patient
    Roberts E.A.
    Yap J.
    Current Treatment Options in Gastroenterology, 2006, 9 (5) : 423 - 431
  • [48] Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD)
    Ajay Duseja
    Naga Chalasani
    Hepatology International, 2013, 7 : 755 - 764
  • [49] THE NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) CONUNDRUM: HOW TO DEFINE IT?
    Mato, J. M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 5 - 5
  • [50] Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging
    Koch, Lisa K.
    Yeh, Matthew M.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2018, 37 : 83 - 90